Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews therapeutic advances published between December 1986 and December 1987 but reports no new research findings; readers are advised to consult the original articles before considering new therapies.

This study in a murine model of alopecia areata found that IFNg is crucial while perforin is not necessary for CD8 T cell-mediated disease development.

In this case-control study, individuals with alopecia areata showed significantly elevated levels of inflammatory markers IL-4, IFN-γ, and CRP, as well as reduced serum Folate and Ferritin, suggesting the condition's multifactorial pathophysiology involves immune activation, systemic inflammation, and micronutrient deficiencies.

This study systematically reviewed literature on paradoxical reactions during biologic treatments for psoriasis, identifying immune dysregulation mechanisms and diverse clinical manifestations, highlighting that mild cases often respond well to topical treatments, while severe cases may require switching to different IL-23 inhibitors.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

In this study, researchers observed elevated levels of epidermal γδ T cells, keratinocytes, and an upregulation of the BST2 gene among immune cells in C3H/HeJ mice with alopecia areata, suggesting a potential role in disease pathogenesis.

This case report describes a 79-year-old woman who developed alopecia universalis shortly after recovering from COVID-19, highlighting its relapsing nature and the challenges in long-term disease management.

Monocyte-derived dendritic cells play a key role in UVB-induced skin sensitivity and inflammation.

Discoid lupus erythematosus involves immune activation and fibrosis around hair follicles, with shared pathways across humans, dogs, and mice, suggesting potential treatments for both humans and animals.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.

This study found that Enz_MoriL, a compound derived from Morus alba L., promotes hair follicle cell proliferation by affecting the Wnt/β-catenin pathway and can counteract an alopecia areata-like condition by suppressing the JAK-STAT signaling in human hair follicle dermal papilla cells.

This study reports on a unique clinical presentation of folliculotropic mycosis fungoides in a 60-year-old man, highlighting complexities in diagnosis due to dense histiocytic infiltration, which led to xanthoma formation before treatment, and obscured lymphomatous features.

The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.

This report highlights a case of a 35-year-old man developing alopecia universalis following alemtuzumab treatment for multiple sclerosis, suggesting potential links between this medication and drug-induced alopecia areata, though the genetic overlap of the conditions may also play a role.

This research explored the roles of various T cell types in chronic alopecia areata, finding that increased severity of lesions and hair loss may be linked to decreased lesional Foxp3+ Tregs, with a notable role for IL-17 and Th17 lymphocytes in the pathological process.

This study explored COVID-related chilblains using transcriptomics and found they showed a distinct interferon and JAK/STAT pathway activation, absent in vaccine-related chilblains, with inflammatory cell types varying over time.

This study found that innate lymphoid cells-type 1 (ILC1) can induce alopecia areata by disrupting hair follicle immune privilege without the involvement of classical CD8+ T cells.

This study found that innate lymphoid cells-type 1 (ILC1lc) can induce alopecia areata (AA) by disrupting hair follicle immune privilege and causing hair follicle dystrophy and regression in both ex vivo and in vivo settings.

This report describes a case of alopecia universalis successfully treated with tofacitinib, though it was associated with increased peripheral blood cytokine levels.

This study found that in chronic alopecia areata, increased IL-17 expression and CD8+CD49a-Trm cell infiltration in hair follicles were associated with more severe histopathologic gradings, while Foxp3+mTreg infiltration decreased.

This study suggests that in alopecia areata, innate lymphoid cells type 1 may contribute to the disease’s pathogenesis by inducing hair follicle changes similarly to CD8+ T cells.

This case report describes a nine-year-old girl with juvenile dermatomyositis and alopecia areata, suggesting a possible etiological link between these coexisting immune-mediated diseases, a previously unreported association.

This study found that plasmacytoid dendritic cells may initiate alopecia areata in mice by overexpressing interferon-alpha.

This study suggests that blood microarray biomarkers may help predict individual treatment response in psoriasis patients, highlighting a distinct blood signature related to inflammation, interferon, and myeloid lineage transcripts.

This case study in a hepatitis B patient observed that pegylated interferon alpha2a treatment may induce localized alopecia areata, which appeared to correlate with treatment administration and discontinuation.

In this study, Yikgeebohyul-tang promoted faster hair regrowth in C57BL6 mice, potentially linked to changes in cytokine levels and epidermal growth factor expression.

This compilation reviews multiple dermatologic studies, reporting findings such as the lack of a psoriasis-susceptibility allele in cluster 17, and highlighting a mouse model for studying hair follicle formation, among others.

This article includes summaries of multiple studies on dermatological topics like Imiquimod's effects on tumors, vitamin C absorption enhancement, and ferritin levels in hair loss, but reports no new results itself.